Menu

Experimental Ebola Vaccine to be Used in DRC Outbreak

As the virus spreads in Democratic Republic of Congo, the World Health Organization is preparing to immunize people as soon as this week.

May 14, 2018
Kerry Grens

Sierra Leone, 2015ISTOCK, HARRY1978The World Health Organization, the government of Democratic Republic of Congo, and Merck have agreed to use Merck’s unapproved Ebola vaccine as an outbreak of the virus expands in DRC.

“The cold chain is on standby, the stockpile is on standby, the teams have been put on standby including up to 40 people that conducted the initial ring vaccination trial in Guinea,” Peter Salama, the World Health Organization’s (WHO) deputy director-general of emergency preparedness and response, said during a United Nations briefing on Friday (May 11), according to Reuters. The Guinea field trial in 2016 found the vaccine to be 100 percent effective at preventing infection among the 6,000 people who received it.

See “Ebola Vaccine Success

So far this spring, 19 people have died of Ebola in DRC. The outbreak is in a remote part of the country, where delivering the vaccine will be a challenge because it must be kept frozen. According to STAT, the cold-chain equipment to keep the vaccine chilled was to arrive in DRC yesterday and the vaccine itself will be shipped from Geneva later this week.

Despite its isolation, the outbreak’s epicenter is just three hours by road to a city of 1 million people, and public health officials are concerned it could spread, The New York Times reports.

See “Two Ebola Cases Confirmed in Democratic Republic of Congo

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.